Zdrowie i gospodarka · 30/09/2020

Patient-Focused Drug Development for Stimulant Use Disorder; Public Meeting; Request for Comments

In the Federal Register notice published on March 19, 2020, the Food and Drug Administration (FDA, the Agency, or we) announced the cancellation of the meeting entitled "Patient-Focused Drug Development for Stimulant Use Disorder" originally scheduled to occur on March 10, 2020, as announced in the Federal Register on February 18, 2020. FDA is announcing a new date for the meeting, to occur in a virtual format. The purpose of the public meeting is to allow FDA to obtain stakeholder perspectives on the impact of stimulant use disorder and views on treatment approaches for stimulant use disorder.